505 COAST BOULEVARD SOUTH, LA JOLLA, CA
CalciMedica, Inc. Files $25 Million Common Stock Prospectus Supplement
Other Events
CalciMedica, Inc. Implements 1-for-5 Reverse Stock Split and Shares Reduction
CalciMedica Stockholders Approve 2023 Amended Equity Incentive Plan
Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
Annual Report to Security Holders
Board Expansion - Evgeny Zaytsev Appointed as Class I Director
Q2
Q1
Amended Annual Report
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Effectiveness Notice
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
S-8 POS